Noxopharm |
High $0.05 |
Low $0.04 |
Trades 61 |
Turnover $61,445 |
Volume 1,415,719 |
| 30 June 2023 at 4:10pm | ||||
|
Market Cap (16-Nov) $11,693,202 (896th) |
Close (30-Jun) $0.043 |
Volume (30-Jun) 1,415,719 |
Shortsold (25-Aug) 4,188 (0.00%) (598th) |
|
52w High $0.110 |
52w Low $0.032 |
P/E - |
EPS -0.02 |
Publications Positive Review of Veyonda in Chemotherapy
NOX released this announcement to the ASX on 30 April 2021, 8:50. The announcement is marked as price sensitive, and is 4 page(s) in length and 312.65kb in size.
You can view all announcements from NOX and see how they appear on a price chart on the announcements page.
At the date of this announcement, NOX was 0.072% short sold according to ASIC data. It was ranked the 452nd most shorted stock on the ASX. It remains ranked 598th as of the latest reported data (25 August 2026).
| Other Recent Announcements from NOX | |
|---|---|
| Change of Director's Interest Notice - FB | 29 June 2023, 12:08 |
| Change of Director's Interest Notice - FB | 19 June 2023, 19:08 |
| Change of Director's Interest Notice - BP | 19 June 2023, 19:08 |
| Publications Positive Review of Veyonda in Chemotherapy | 30 April 2021, 8:50 |
| Notice of General Meeting/Proxy Form | 29 April 2021, 8:15 |
| March Quarterly Activities Report and Appendix 4C | 27 April 2021, 9:04 |
| Veyonda Showing Potential to Prevent Cytokine Storm | 22 April 2021, 11:51 |
If you were already registered, log in here.